Glide Pharma Appoints Dr Mark Carnegie-Brown as Chief Executive

Glide Pharma Appoints Dr Mark Carnegie-Brown as Chief Executive

OXFORD, UK – 6 March 2013 – Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced the appointment of Dr. Mark Carnegie-Brown as its Chief Executive Officer.
Dr. Carnegie-Brown brings to Glide 25 years' experience of the life sciences sector. Previously, he was CEO of Evolutec, a biological drug development business, where he led a successful IPO and established the company's clinical and manufacturing programmes. He was also CEO of Aenova, a pharmaceutical tablet and capsule manufacturer, where he led the integration of the Swisscaps and Dragenopharm organisations. Dr. Carnegie-Brown started his career in R&D at ICI and subsequently held a number of commercial roles before becoming General Manager of Zeneca's UK and Eire business.

"I am delighted to welcome Mark to Glide Pharma," said Mark Kirby, Glide Pharma's Chairman. "His research and commercial experience, and in particular his expertise in building successful clinical and manufacturing programmes, will prove invaluable as Glide scales up its capabilities and advances the development of its in-house programmes. I would also like to take this opportunity to thank Dr Ian Smith, our previous CEO, for his contribution to the success of Glide, and I look forward to his continuing support as a member of the company's Board."

"Glide is in a truly transformational period in its development, and I am delighted to have this opportunity to lead the organisation," said Dr. Mark Carnegie-Brown, Glide Pharma's CEO. "Having recently completed a successful major fundraising and received significant funding from the UK government-backed Biomedical Catalyst, Glide is well positioned for growth, and I look forward to leading the team as we accelerate the development of the company's solid dose delivery technology."

About the Glide SDI® solid dose injector

The Glide SDI® is an innovative needle-free delivery system. The reusable injector uses a spring mechanism to administer a tiny solid dosage below the patient's skin, where it dissolves and releases the pharmaceutical. Glide's solid dose formulations eliminate the risk of needle-stick injuries and avoid time- consuming reconstitution. They also have the potential to modify the release of medicines and to improve stability, removing the need for refrigeration. The one-click action, pen-sized device is extremely easy to use, with medicines supplied in pre-filled disposable cassettes, making it ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI® to traditional needle and syringe.

About Glide Pharma

Glide Pharma is a pharmaceutical development and device company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI ®. Glide Pharma has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.


Dr. Mark Carnegie-Brown


Glide Pharma

Tel: +44 (0)8700 853700

Rob Budge

RJB Communications

Tel: +44 (0)1865 760969

Mobile: +44 (0)7710 741241

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.